Sajjad A. Bhatti

Medical Director of Thoracic Cancers

Last publication 2025 Last refreshed 2026-05-16

faculty

6 h-index 22 pubs 158 cited

Biography and Research Information

OverviewAI-generated summary

Sajjad A. Bhatti's research focuses on the treatment outcomes and survival of older patients with non-small-cell lung cancer, particularly those with synchronous brain metastases. His work investigates the efficacy and safety of immune checkpoint inhibitors (ICIs) and chemotherapy, both as first-line treatments and subsequent therapies. Bhatti has also explored the role of cranial irradiation in conjunction with ICIs for this patient population. His publications include studies on the real-world survival of patients receiving ICI treatment versus chemotherapy, the efficacy of two-year fixed versus continuous ICI therapy, and the use of ICIs as subsequent treatment in older adults with non-small-cell lung cancer and brain metastases. He also has a publication on sudden vision loss as a presenting symptom of metastatic lung adenocarcinoma. Bhatti's scholarship metrics include an h-index of 2, with 5 total publications and 15 total citations.

Metrics

  • h-index: 6
  • Publications: 22
  • Citations: 158

Selected Publications

  • Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)
  • An example of long-term remission in oligorecurrent relapsed small-cell lung cancer, following single modality radiation therapy (2025)
  • Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation. (2025)
  • In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide. (2025)
  • Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025)
  • Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)
    1 citation DOI OpenAlex
  • Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)
    2 citations DOI OpenAlex
  • Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023)
    12 citations DOI OpenAlex
  • Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows. (2023)
  • Exploring the association between medical marijuana cardholder status and antiemetic overuse. (2023)
  • Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench (2022)
    6 citations DOI OpenAlex
  • A RARE CASE OF DESMOPLASTIC SMALL ROUND CELL TUMOR WITH LEPTOMENINGEAL CARCINOMATOSIS (2022)
    1 citation DOI OpenAlex
  • Immune Checkpoint Inhibitors—Associated Cardiotoxicity (2022)
    56 citations DOI OpenAlex

View all publications on OpenAlex →

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics